1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Scleroderma, Systemic in 3 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study aimed firstly to describe pulmonary inflammation and fibrosis induced by HOCl in mice, and secondly to determine whether fasudil, a selective inhibitor of ROCK, could prevent lung and skin fibroses in HOCl-injected mice." | 1.43 | RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. ( Batteux, F; Bei, Y; Chéreau, C; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Le-Dong, NN; Nicco, C; Tiev, KP, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pernis, AB | 1 |
| Ricker, E | 1 |
| Weng, CH | 1 |
| Rozo, C | 1 |
| Yi, W | 1 |
| Bei, Y | 1 |
| Hua-Huy, T | 1 |
| Nicco, C | 1 |
| Duong-Quy, S | 1 |
| Le-Dong, NN | 1 |
| Tiev, KP | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| Dinh-Xuan, AT | 1 |
| Fava, A | 1 |
| Wung, PK | 1 |
| Wigley, FM | 1 |
| Hummers, LK | 1 |
| Daya, NR | 1 |
| Ghazarian, SR | 1 |
| Boin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon[NCT03984422] | 120 participants (Anticipated) | Observational | 2020-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Scleroderma, Systemic
| Article | Year |
|---|---|
Rho Kinases in Autoimmune Diseases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Arthritis, Rheumatoid; Autoimmune Di | 2016 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Scleroderma, Systemic
| Article | Year |
|---|---|
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Scleroderma, Systemic
| Article | Year |
|---|---|
RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Disease Models, Animal; Female; Hypo | 2016 |